Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>Resources>White Papers>This White Paper
  White Papers
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Scroll Up
Scroll Down

Value to the Fore: Flexible CRO Solutions Aim to Improve Pipeline Success
Bookmark and Share


R&D outsourcing is widely used by pharmaceutical, biotechnology, agricultural and related industries. In order for this to continue, CRO's will need to make higher value contributions i collaborative drug discovery programs.

Trends indicate a return to value, as Contract Research Organizations (CROs) continue to grow their skill sets and ally with the global R&D industry to tap flexible solutions aimed at improving pipeline success. Bruce Molino, Ph.D., Senior Director of Medicinal Chemistry, and Christopher Conway, Senior Director of Business Development, AMRI, analyze the increasing demand for R&D outsourcing and examine how CROs are evolving to better meet industry needs.

Further Information

Related Content

AMRI To Acquire Aptuit Drug Product Development Businesses
Significantly expands AMRI's analytical services capabilities and extends drug product development services to include sterile injectable formulation development.
Friday, January 09, 2015
AMRI Announces Senior Level Leadership Appointment
The appointment of Michael A. Luther, Ph.D. as Senior Vice President of Discovery sees AMRI expanding its biology capabilities.
Thursday, October 17, 2013
AMRI and Ono Broaden SMARTSOURCING™ Collaboration
New agreement extends drug discovery and development collaboration between the companies.
Friday, April 26, 2013
AMRI Further Expands Discovery Capabilities in India
Two strategic hires bring additional flexibility to global drug discovery operations.
Thursday, June 21, 2012
AMRI Signs Exclusive Option to License its Tubulin Inhibitor Program for Cancer
Agreement demonstrates AMRI’s commitment to value creation from its proprietary portfolio of compounds and programs.
Friday, April 06, 2012
Third Compound from AMRI Bristol-Myers Squibb Collaboration Selected for Preclinical Development
AMRI to receive a $750,000 milestone payment from licensing agreement.
Wednesday, November 11, 2009
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos